Freeline Therapeutics’ $120 Million Series C Investment

Paolo Bossi

Latham & Watkins advised Novo Holdings A/S (Novo) as the lead investor in the investment. Freeline Therapeutics raised US$120 million in its Series C investment, co-led…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

…

This content is for Standard 1 Year members only.
Login Join Now